Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00944047 · ClinicalTrials.gov registry record · Phase 2
Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression
A Phase 2 study, sponsored by University of Kansas Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT00944047 is a Phase 2 study that has completed, run by University of Kansas Medical Center. The registered enrollment target is 32 participants.
The verdict
NCT00944047, a Phase 2 study, has completed, sponsored by University of Kansas Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if there is a benefit of adding Herceptin (trastuzumab) to standard chemotherapy in this type of breast cancer.
Interventions
- DRUG Doxorubicin
- DRUG nab-paclitaxel
- DRUG cyclophosphamide
- DRUG trastuzumab
- BIOLOGICAL Growth Factor Support
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2009-07 |
| Est. Completion | 2017-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00944047
The ClinicalTrials.gov registry entry for NCT00944047 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Doxorubicin is the first listed.
NCT00944047 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00944047 about?
NCT00944047 is a clinical study titled "Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression". The purpose of this study is to find out if there is a benefit of adding Herceptin (trastuzumab) to standard chemotherapy in this type of breast cancer.
What is the current status of trial NCT00944047?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2009-07. Estimated completion is 2017-08.
What interventions are being tested in trial NCT00944047?
The interventions under investigation include: Doxorubicin (DRUG), nab-paclitaxel (DRUG), cyclophosphamide (DRUG), trastuzumab (DRUG), Growth Factor Support (BIOLOGICAL).
Who is sponsoring clinical trial NCT00944047?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.